Early responses of <i>EGFR</i> circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment

Fumio Imamura(Osaka International Cancer Institute), Kikuya Kato(Unknown)

Oncotarget

September 30, 2016

10.18632/oncotarget.12373

Cited by 22

Related Papers

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2008|365

Monitoring gastric cancer progression with circulating tumour DNA

|British Journal of Cancer|2014|103

High-fidelity target sequencing of individual molecules identified using barcode sequences:<i>de novo</i>detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

|DNA Research|2015|88

Usefulness of ultrathin bronchoscopy in diagnosis of lung cancer

|Lung Cancer|2004|58

Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics

|Diagnostics|2023|26